Psychedelic Therapy: A Primer for Primary Care Clinicians—Ibogaine

1Department of Psychiatry & Behavioral Sciences, Stanford University, Palo Alto, CA;

2Centre for Eudaimonia and Human Flourishing, University of Oxford, Oxford, United Kingdom;

3Department of Psychiatry, University of Oxford, Oxford, United Kingdom;

4University of Nevada, Reno School of Medicine, Reno, NV;

5Department of Neurology, Carson Tahoe Health, Carson City, NV;

6Department of Anesthesiology, University of Washington School of Medicine, Seattle, WA;

7Keck School of Medicine, University of Southern California, Los Angeles, CA;

8Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY;

9Teachers College, Columbia University, New York, NY;

10Fermata Health, Brooklyn, NY; and

11Acacia Clinics, Sunnyvale, CA.

*Address for correspondence: Kenneth Shinozuka, BA, Centre for Eudaimonia and Human Flourishing, 7 Stoke Place, Headington, Oxford OX3 9BX, United Kingdom. E-mail: [email protected]

The authors have no conflicts of interest to declare.

K. Cherian and K. Shinozuka contributed equally to this work.

留言 (0)

沒有登入
gif